⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2024Open Access

Supplementary Figure S1 from Targeting CD33⁺ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window

Tero Satomaa Henna Pynnönen Olli Aitio Jukka O. Hiltunen Virve Pitkänen Tuula Lähteenmäki Titta Kotiranta Annamari Heiskanen Anna‐Liisa Hänninen Ritva Niemelä Jari Helin Heikki Kuusanmäki Ida Vänttinen Ramji Rathod Anni I. Nieminen Emrah Yatkin Caroline A. Heckman Mika Kontro Juhani Saarinen

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Characterization of LN-mcvc-MMAE DAR4 (lintuzumab vedotin).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Satomaa et al. (2024) studied this question.

synapsesocial.com/papers/68e5e0e0b6db643587574d64 https://doi.org/10.1158/1535-7163.26424080.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S1 from Targeting CD33<sup>+</sup> Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window2024
2Supplementary Figure S2 from Targeting CD33<sup>+</sup> Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window2024
3Supplementary Figure S2 from Targeting CD33<sup>+</sup> Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window2024
4Supplementary Figure S4 from Targeting CD33<sup>+</sup> Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window2024
5Supplementary Figure S4 from Targeting CD33<sup>+</sup> Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window2024

More related papers

Supplementary Figure S3 from Targeting CD33<sup>+</sup> Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window2024
Supplementary Figure S3 from Targeting CD33<sup>+</sup> Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window2024
Supplementary Data from Targeting CD33<sup>+</sup> Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window2024